SCIENTIFIC REPORTS, A Phase I Clinical Trial with Ex Vivo Expanded Recipient Regulatory T Cells in Living Donor Kidney Transplants” April 2018.
Download Full Report
TRACT Therapeutics, Inc. Launches the TRACT CryoBanking Program™ to Collect and Bank a Patient’s Immune Cells for Future Treatment
May 31, 2016 08:58 AM Central Daylight Time CHICAGO (BUSINESS WIRE) – TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory Tcell (Treg) therapy, announced today that it has launched the TRACT CryoBanking Program to enable individuals to donate their blood consisting of their immune cells for future treatments as Continue reading
TRACT Therapeutics, Inc. Received FDA Approval for a Phase 2 Trial Using a Patient’s Immune Cells to Prevent Organ Rejection
April 29, 2016 15:07 UTC CHICAGO–(BUSINESS WIRE)– TRACT Therapeutics, Inc., a biotechnology company developing personalized regulatory T-cell (Treg) therapy, announced today that it received Food and Drug Administration (FDA) approval to initiate a Phase 2 clinical trial to investigate the efficacy and safety of its novel therapy for kidney transplant Continue reading
TRACT Therapeutics, Inc. Completes Phase I Safety Trial
TRACT Therapeutics, Inc. Completes Phase I Safety Trial Using a Patient’s Immune Cells to Prevent Organ Rejection Safety Data Presented at the American Transplant Congress Meeting Demonstrated Excellent Patient Tolerability and Supports the Start of a Phase II Trial Additional Data Analysis Showed Positive Signals Toward Efficacy CHICAGO–(BUSINESS WIRE)– TRACT Continue reading
TRACT Therapeutics, Inc. in White City News
“A kidney transplant that lasts for life. It’s the ultimate goal. But the drugs that keep a donor organ going also pose the greatest threat. Now a new approach to fighting off rejection. Chicago based TRACT Therapeutics aims to remove the need for organ transplant patients to take immunosuppressive drugs by Continue reading